Azienda Universitaria Ospedaliera Consorziale Policlinico Bari
- Address
- Piazzale Giulio Cesare 11, 70124 Bari, Italy
Cardiovascular Diseases
At Azienda Universitaria Ospedaliera Consorziale Policlinico Bari, the University Cardiology team is conducting research in cardiovascular medicine focused on heart failure and obesity. These studies are designed to assess whether new treatment approaches can better reduce heart-related events and improve outcomes for people living with complex chronic heart disease.
- Heart failure with preserved or mildly reduced ejection fraction
- Obesity as a major factor in cardiovascular risk
- Testing new therapies to lower hospitalizations and cardiovascular death
This work reflects a strong interest in improving both symptom control and long-term protection for patients with overlapping cardiac and metabolic conditions.
Hemic and Lymphatic Diseases
The site is also involved in hematology research on aggressive B-cell acute lymphoblastic leukemia, including forms linked to Philadelphia chromosome abnormalities. The studies aim to evaluate whether newer treatment combinations can improve survival while maintaining an acceptable safety profile in children, adolescents, and young adults.
- Philadelphia chromosome positive B-cell acute lymphoblastic leukemia
- ABL-class Philadelphia chromosome-like B-cell acute lymphoblastic leukemia
- Evaluating treatment effectiveness and safety in newly diagnosed disease
This research focuses on improving outcomes for patients with high-risk blood cancers through more targeted and coordinated treatment strategies.
Nutritional and Metabolic Diseases
Clinical trials in metabolic disease at this hospital are centered on obesity, overweight, and type 2 diabetes. The main goal is to test whether new therapies can support meaningful weight management and help address the broader health burden associated with metabolic disorders.
- Obesity and overweight
- Type 2 diabetes
- Evaluating new approaches for weight reduction and metabolic control
These studies are especially relevant for patients whose weight-related conditions may also increase the risk of cardiovascular complications.
Neoplasms
In the field of oncology, the research program includes studies in advanced or metastatic extrapulmonary neuroendocrine carcinoma. The trials are designed to determine whether adding a new investigational therapy to standard chemotherapy can improve overall survival for patients with this difficult-to-treat cancer.
- Advanced or metastatic extrapulmonary neuroendocrine carcinoma
- Testing new treatment combinations in solid tumors
- Improving survival in previously untreated advanced cancer
This area highlights the site’s broader commitment to developing better cancer treatments through clinical research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 142 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 122 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 37 by active trials.
- 1Boehringer Ingelheim Espana S.A.4active
lock +36 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.4trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Universitaria Ospedaliera Consorziale Policlinico Bari
lock Showing 1 of 52 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors | Exelixis Inc. | Phase IV | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 142 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 4 | Unknown | 2023-09-20 | 2025-09-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.